ADVANCE Studies Ralinepag (IP receptor agonist)
NCE / Novel Biologics therapeutic platform
ADVANCE Studies Ralinepag (IP receptor agonist)
ADVANCE OUTCOMES – Phase 3, randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of ralinepag in subjects with pulmonary arterial hypertension (PAH) by evaluating ralinepag’s impact on time to clinical worsening in patients with PAH. ADVANCE CAPACITY is an additional Phase 3 clinical trial to evaluate ralinepag’s impact on exercise capacity in patients with PAH.
Ralinepag is a novel, once daily IP receptor agonist undergoing Phase 3 studies for PAH. Ralinepag has demonstrated superiority and improved pharmacology over selexipag in nonclinical studies and proof of concept in a Phase 2 clinical trial in PAH.
Ralinepag is a development-stage product not approved for sale in any jurisdiction.
